What the FDA labels say about taking them together
Gatifloxacin and pimavanserin
Pimavanserin's FDA label of June 18, 2026 names gatifloxacin in its warnings and precautions section; the gatifloxacin label PlainMeds reads does not name pimavanserin. The pimavanserin label: “The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain …”
Check it at the source: the gatifloxacin FDA label on DailyMed (effective September 8, 2016, Allergan, Inc.); the pimavanserin FDA label on DailyMed (effective June 18, 2026, Acadia Pharmaceuticals Inc.).
What does the gatifloxacin label say about pimavanserin?
Gatifloxacin's label (effective September 8, 2016) does not name pimavanserin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ZYMAXID), NDA022548 (Abbvie), as published by Allergan, Inc., effective September 8, 2016 (SPL set 1160b16c-929a-4e85-9c0b-1d8c96a7678b), via openFDA; the full label on DailyMed
What does the pimavanserin label say about gatifloxacin?
Pimavanserin label, warnings and precautionsThe use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) [see Drug Interactions (7.1) ].
Source: FDA drug label (NUPLAZID), Acadia Pharmaceuticals Inc., effective June 18, 2026 (SPL set 1e6bea44-57d6-4bac-9328-46e1ee59f83b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gatifloxacin | Pimavanserin | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $8.85 per mL 0.5% eye drops | $170.50 per capsule 34 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once